BofA analyst Tim Anderson lowered the firm’s price target on Moderna (MRNA) to $24 from $25 and keeps an Underperform rating on the shares. Q2 total revenues were ahead of expectations, led entirely by COVID, notes the analyst, who also points out that 2025 revenue guidance was trimmed to $1.5B-$2.2B from $1.5B-$2.5B, reflecting a shift in vaccine delivery timing to the United Kingdom.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRNA: